CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer

(2019) Matthew J. Watt et al.   Science Translational Medicine

Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy

(2019) Gergana E. Stoykova et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

(2019) Celestia S. Higano et al.   CANCER

CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis

(2018) Ying-nan Wang et al.   ONCOGENE

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer

(2018) Hung-Ming Lam et al.   Frontiers in Oncology

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

(2018) Giorgia Zadra et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Diagnosis and Treatment of Prostate Cancer

(2017) Mark S. Litwin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

(2017) Loren M. Lasko et al.   NATURE

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer

(2017) W Han et al.   ONCOGENE

Lipid degradation promotes prostate cancer cell survival

(2017) Harri M. Itkonen et al.   Oncotarget

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

(2017) Thomas W. Flaig et al.   Oncotarget

Prostate cancer

(2016) Gerhardt Attard et al.   LANCET

The role of fatty acid β-oxidation in lymphangiogenesis

(2016) Brian W. Wong et al.   NATURE

Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer

(2016) Q Qu et al.   Cell Death & Disease

Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation

(2016) Eoin McDonnell et al.   Cell Reports

Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer

(2016) Jun Hyoung Park et al.   Cell Reports

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

(2016) Paul Toren et al.   PLoS One

Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level

(2015) Theodoros Karantanos et al.   EUROPEAN UROLOGY

Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[18F]Fluoro-d-Glucose Uptake in Prostate Cancer Mouse Xenografts

(2015) Isabel R. Schlaepfer et al.   MOLECULAR IMAGING AND BIOLOGY

Fatty acid carbon is essential for dNTP synthesis in endothelial cells

(2015) Sandra Schoors et al.   NATURE

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer

(2014) I. R. Schlaepfer et al.   MOLECULAR CANCER THERAPEUTICS

Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer

(2012) P. J. Saylor et al.   CLINICAL CANCER RESEARCH

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors

(2012) Elahe A. Mostaghel et al.   PLoS One

Lipids and prostate cancer

(2012) Janel Suburu et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

Alternatively spliced androgen receptor variants

(2011) Scott M Dehm et al.   ENDOCRINE-RELATED CANCER

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reducing prohibitin increases histone acetylation and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens

(2011) D A Dart et al.   ONCOGENE

Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells

(2010) Lisa S. Pike et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy

(2009) Li-Xin Zhou et al.   ASIAN JOURNAL OF ANDROLOGY

Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer

(2009) D. S. Welsbie et al.   CANCER RESEARCH

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

(2009) Ismael Samudio et al.   JOURNAL OF CLINICAL INVESTIGATION

Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer

(2009) Toshiro Migita et al.   JNCI-Journal of the National Cancer Institute

Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone

(2009) J.P. Michiel Sedelaar et al.   PROSTATE